How will the new landscape of hepatitis C treatments affect patients?

The development of new therapeutic agents is set to revolutionise treatment of hepatitis C. These new therapies represent a real transformation in care; offering fewer, milder side effects, a shorter treatment duration and dramatically improved success rates. However, they are expensive and there is a possibility that the virus could become resistant if adherence is sub-optimal. This raises fresh questions around medical funding and the types of support patients will need in order to get the best results from their treatments.

For this 22 April webinar we bring together a panel of experts in hepatitis C to discuss this important topic, including a healthcare funder, a pharma medical director and an adherence researcher.

Apr 22 2014

60 mins